Evidence map›Paper›PMID 39684550›Full record

ReviewInternational journal of molecular sciences2024

Notch Inhibitors and BH3 Mimetics in T-Cell Acute Lymphoblastic Leukemia.

Ilaria Sergio, Claudia Varricchio, Federica Squillante, Noemi Martina Cantale Aeo, Antonio Francesco Campese, Maria Pia Felli

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. c-Medical sciences (Basel, Switzerland) · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ilaria SergioDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0001-9148-0959
Claudia VarricchioDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Federica SquillanteDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Noemi Martina Cantale AeoDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Antonio Francesco CampeseDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Maria Pia FelliDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-5765-2611

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with poor response to conventional therapy, derived from hematopoietic progenitors committed to T-cell lineage. Relapsed/Refractory patients account for nearly 20% of childhood and 45% of adult cases. Aberrant Notch signaling plays a critical role in T-ALL pathogenesis and therapy resistance. Notch inhibition is a promising therapeutic target for personalized medicine, and a variety of strategies to prevent Notch activation, including

Indexed as

ApoptosisPrecursor T-Cell Lymphoblastic Leukemia-LymphomaReceptors, NotchAmyloid Precursor Protein SecretasesAnimalsAntineoplastic AgentsHumansProto-Oncogene Proteins c-bcl-2Signal TransductionAmyloid Precursor Protein SecretasesAntineoplastic AgentsProto-Oncogene Proteins c-bcl-2Receptors, NotchBcl-2 family proteinsBH3 mimeticsNotchNotch inhibitorsT-cell leukemia

Identifiers

PMID39684550
PMCPMC11641392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.